{
    "Trade/Device Name(s)": [
        "MP DOA-10 Panel Test Cup",
        "MP DOA-11 Panel Test Cup"
    ],
    "Submitter Information": "MP Biomedicals, LLC",
    "510(k) Number": "K162395",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003809",
        "K033566",
        "K051958"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO",
        "DIS",
        "DJG",
        "DJR",
        "DKZ",
        "JXM",
        "LAF",
        "LCM",
        "LDJ"
    ],
    "Summary Letter Date": "May 9, 2017",
    "Summary Letter Received Date": "May 10, 2017",
    "Submission Date": "May 24, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.3250",
        "21 CFR 862.3100",
        "21 CFR 862.3150",
        "21 CFR 862.3170",
        "21 CFR 862.3870",
        "21 CFR 862.3620",
        "21 CFR 862.3610",
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Cocaine and cocaine metabolite test system",
        "Amphetamine test system",
        "Barbituate test system",
        "Benzodiazepine test system",
        "Cannabinoid test system",
        "Methadone test system",
        "Methamphetamine test system",
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Barbiturates",
        "Benzodiazepine",
        "Buprenorphine",
        "Cannabinoids",
        "Cocaine",
        "Methadone",
        "Methamphetamine",
        "Opiates",
        "Oxycodone",
        "Phencyclidine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Test Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow",
        "Competitive binding"
    ],
    "Methodologies": [
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Test Cup",
        "Panel",
        "Point-of-care"
    ],
    "Document Summary": "FDA 510(k) summary for MP DOA-10 and MP DOA-11 Panel Test Cups for qualitative screening of drugs of abuse in urine using immunochromatographic lateral flow technology.",
    "Indications for Use Summary": "Intended for qualitative detection of up to ten or eleven drug substances in human urine in a point-of-care setting as a preliminary test; requires confirmatory method for positive results.",
    "fda_folder": "Toxicology"
}